• Explore /
  • Poster
  • / Multicenter phase II study of FOLFOX or biweekly XELOX and cetuximab as first-line treatment in patients with wild-type KRAS/BRAF metastatic colorectal cancer (mCRC) (FLEET study).

Multicenter phase II study of FOLFOX or biweekly XELOX and cetuximab as first-line treatment in patients with wild-type KRAS/BRAF metastatic colorectal cancer (mCRC) (FLEET study).

Abstract Poster

Authors

null

Ho Min Kim

Department of Surgery, Osaka Rosai Hospital

Ho Min Kim , Hitoshi Soda , Shoichi Hazama , Takao Takahashi , Naoki Nagata , Masahito Kotaka , Emiko Kono , Itsurou Terada , Mutsumi Fukunaga , Koji Oba , Junichi Hasegawa , Junichi Sakamoto , Hideyuki Mishima

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon and Rectum

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

UMIN000003253

Citation

J Clin Oncol 31, 2013 (suppl 4; abstr463)

DOI

10.1200/jco.2013.31.4_suppl.463

Abstract #

463

Poster Bd #

C19

Abstract Disclosures

Similar Posters

First Author: Ann-Lii Cheng

First Author: Richard Adams

First Author: Jianming Xu

First Author: Samuel A. Jacobs